晚期非小细胞肺癌抗血管生成治疗:文献复习及病例报道

doi:10.3969/j.issn.1009-976X.2015.06.003

摘要/Abstract

摘要： 【摘要】〓肺癌是我国死亡率最高的癌症,其中非小细胞肺癌占多数。近年来研究表明,抗血管生成药物在多种实体瘤包括非小细胞肺癌中表现出了显著的疗效。阿帕替尼作用于血管内皮生长因子受体(VEGFR),临床研究证实目前其主要适应症为晚期胃癌。近年来在晚期非小细胞肺癌患者中应用阿帕替尼的临床实践日益增多,但相关报道极少。现将本院在晚期非小细胞肺癌中应用阿帕替尼的临床病例报告如下并做相关文献复习。

关键词: 非小细胞肺癌, 阿帕替尼, 抗血管生成

Abstract: 【Abstract】〓Lung cancer leads in the highest mortality rate of cancers in our country, the majority of which is non-small-cell lung caner. Latest studies prove that anti-angiogenesis drugs exert a remarkable effect on the therapy of NSCLC. By acting on VEGFR, apatinib is testified to treat patients diagnosed with advanced gastric carcinoma. Numerous clinical practices have been applied for the past years in which apatinib treat the patients with NSCLC. However, relevant reports are rarely seen. Therefore we tend to report two cases in which apatinib is used in the treatment of advanced lung cancer and review the relevant articles.

Key words: Apatinib, Non-small cell lung cancer, Anti-angiogenesis

中图分类号:

R734.2

丁林江志敏李怀李青剑姚和瑞. 晚期非小细胞肺癌抗血管生成治疗:文献复习及病例报道[J]. 岭南现代临床外科, 2015, 15(06): 656-660.

Ding Lin, Jiang Zhimin, Li Huai, Li Qingjian, Yao Herui. Anti-angiogenesis treatment in advanced non-small cell lung cancer: case report and review of literature[J]. Lingnan Modern Clinics in Surgery, 2015, 15(06): 656-660.

参考文献

[1]. Zhi XY, Zou XN, Hu M, Jiang Y, Jia MM, Yang GH. Increased lung cancer mortality rates in the Chinese population from 1973-1975 to 2004-2005: An adverse health effect from exposure to smoking[J]. Cancer. 2015;121 Suppl 17:3107-12.
[2]. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors[J]. Annals of translational medicine. 2014;2(12):123.
[3]. Liu L, Yu H, Huang L, Shao F, Bai J, Lou D, et al. Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer[J]. OncoTargets and therapy. 2015;8:921-8.
[4]. Youssoufian H, Hicklin DJ, Rowinsky EK. Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy[J]. Clinical Cancer Research. 2007;13(18):5544s-8s.
[5]. C D, S M, N S. Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
A Meta-analysis[J]. JAMA. 2004;292:470-84.
[6]. Stinchcombe TE. Targeted therapy of advanced non-small cell lung cancer:the role of bevacizumab[J]. Biologics:Target & Therapy 2007:I(3) I85-194. 2007.
[7]. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. The New England journal of medicine. 2006;355(24):2542-50.
[8]. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. The New England journal of medicine. 2009;361(10):947-57.
[9]. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. The Lancet Oncology. 2012;13(3):239-46.
[10]. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. The Lancet Oncology. 2011;12(8):735-42.
[11]. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(5):777-84.
[12]. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(5):785-94.
[13]. Janne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2063-9.
[14]. Paez JG, J?nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy[J]. Science. 2004;304(5676):1497-500.
[15]. Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, et al. Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System[J]. Molecular and clinical oncology. 2014;2(6):991-6.
[16]. Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, et al. Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome[J]. New England Journal of Medicine. 2005;353(2):133-44.
[17]. Skov BG, H?gdall E, Clementsen P, Krasnik M, Larsen KR, S?rensen JB, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population[J]. APMIS. 2015;123(2):108-15.
[18]. Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital[J]. PloS one. 2013;8(2):e56011.
[19]. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(11):2184-91.
[20]. Tian S, Quan H, Xie C, Guo H, Lu F, Xu Y, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer science. 2011;102(7):1374-80.
[21]. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk‐1 is essential for VEGF‐A‐dependent activation of PLC‐γ and DNA synthesis in vascular endothelial cells[J]. The EMBO Journal. 2001;20(11):2768-78.
[22]. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(2):826-32.
[23]. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease[J]. Nat Med. 1995;1(1):27-30.
[24]. Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC cancer. 2010;10:529.
[25]. Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC cancer. 2014;14:820.
[26]. Qin S. Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial[J]. J Clin Oncol (Meeting Abstracts). 2014;32(15_suppl):4003-.
[27]. De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, et al. Clinical management of advanced gastric cancer: the role of new molecular drugs[J]. World journal of gastroenterology : WJG. 2014;20(40):14537-58.
[28]. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(26):3219-25.